As of Wednesday close, Bristol-Myers Squibb Company’s (NYSE:BMY) stock was up $0.15, moving up 0.26 percent to $58.78. The average number of shares traded per day over the past five days has been 15,319,400 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.87 fall in that time frame. In the last twenty days, the average volume was 11,646,785, while in the previous 50 days, it was 11,314,094.
Since last month, BMY stock retreated -5.06%. Shares of the company fell to $58.33 on 09/18/23, the lowest level in the past month. A 52-week high of $81.43 was reached on 02/06/23 after having rallying from a 52-week low of $58.33. Since the beginning of this year, BMY’s stock price has dropped by -18.30% or -$13.17, and marked a new high 9 times. However, the stock has declined by -27.82% since its 52-week high.
BMY stock investors should be aware that Bristol-Myers Squibb Company (BMY) stock had its last reported insider trading activity 28 days ago on Aug 24. Powell Ann, the EVP, Chief Human Resources of the company, disposed of 17,986 shares for $61.25 on Aug 24. It resulted in a $1,101,642 divestment by the insider. Plenge Robert M sold 732 shares at an average price of $61.14 on Aug 03. The insider now owns 6,584 shares following the transaction. On May 03, EVP & President, Research VESSEY RUPERT sold 50,385 shares at $67.06 apiece. The transaction was valued at $3,378,818.
Valuation Metrics
Right now, Bristol-Myers Squibb Company (BMY) has a P/E ratio of about 15.65. The stock’s beta is 0.41. Besides these, the trailing price-to-sales (P/S) ratio of 2.74, the price-to-book (PB) ratio of 3.85, and the price-to-cash flow ratio of 11.54 may also be considered.
The latest dividend of $0.57 per share was paid out, remained unchanged from last year’s $0.57. On Thursday December 8 2022, a $0.03 dividend increase was announced.
Financial Health
In the three months ended June 29, Bristol-Myers Squibb Company’s quick ratio stood at 1.30, while its current ratio was 1.40, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 1.08, and the total debt-to-equity ratio was 1.18. On the profitability front, the trailing twelve-month gross margin is 77.10% percent. In the year ended June 29, EBITDA margin amounted to 42.37%, whereas operating margins totaled 22.00%. Based on annual data, BMY earned $36.02 billion in gross profit and brought in $46.16 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 11.80%. Return on equity (ROE) for the past 12 months was 25.00%.
In Bristol-Myers Squibb Company’s quarter-end financial report for June 29, it reported total debt of $34.66 billion. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. BMY’s revenue fell -5.89% to $11.34 billion during the quarter, while net income inched up to $11.23 billion. While analysts expected Bristol-Myers Squibb Company to report $1.98 quarterly earnings, the actual figure was $1.75 per share, beating the consensus estimate by -11.60%. During the quarter, the company generated $4.29 billion in EBITDA. The liabilities of Bristol-Myers Squibb Company were 61.46 billion at the end of its most recent quarter ended June 29, and its total debt was $39.21 billion. The value of shareholders’ equity is $2.09 billion.
Technical Picture
This quick technical analysis looks at Bristol-Myers Squibb Company’s (BMY) price momentum. With a historical volatility rate of 11.35%, the RSI 9-day stood at 31.85% on 20 September.
With respect to its five-day moving average, the current Bristol-Myers Squibb Company price is down by -1.46% percent or -$0.87. At present, BMY shares trade -4.98% below its 20-day simple moving average and -13.06% percent below its 100-day simple moving average. However, the stock is currently trading approximately -6.39% below its SMA50 and -27.32% below its SMA200.
Stochastic coefficient K was 7.34% and Stochastic coefficient D was 5.64%, while ATR was 0.92. Given the Stochastic reading of 10.71% for the 14-day period, the RSI (14) reading has been calculated as 35.54%. As of today, the MACD Oscillator reading stands at -0.90, while the 14-day reading stands at -1.34.
Analyst Ratings
HSBC Securities launched its rating on Bristol-Myers Squibb Company (NYSE: BMY) to a Reduce in a note to investors on July 14, 2023. Bristol-Myers Squibb Company (BMY) has been rated Overweight by analysts. According to 2 brokerage firms, BMY is a sell, and 10 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Bristol-Myers Squibb Company stock as buy, with 12 recommending it as overweight.
With a median target price of $74.00, the current consensus forecast for the stock is $55.00 – $90.00. Based on these forecasts, analysts predict Bristol-Myers Squibb Company (BMY) will achieve an average price target of $72.90.
